Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
A. Necchi
Observed name:
Andrea Necchi
Institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
Fondazione IRCCS Istituto Nazionale dei Tumori,
IRCCS San Raffaele Roma
Observed institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
Fondazione IRCCS Istituto Nazionale dei Tumori,
IRCCS San Raffaele Roma,
Tisch Cancer Institute,
Icahn School of Medicine at Mount Sinai
show all 6
ORCID:
0000-0002-3007-2756
Observed ORCID:
0000-0002-3007-2756
OpenAlex ID:
A5064364440
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
2024
·
J.E. Rosenberg
, M.D. Galsky
, et al.
·
ESMO Open
·
63
PDF
READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma
2024
·
L. Antonuzzo
, M. Maruzzo
, et al.
·
ESMO Real World Data and Digital Oncology
·
42
Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
2019
·
A. Bamias
, K. Tzannis
, et al.
·
Annals of Oncology
·
17
LBA105 Results from SunRISe-1 in patients (Pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy
2023
·
A. Necchi
, J.M. Jacob
, et al.
·
Annals of Oncology
·
16
PDF
LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis
2024
·
P. Grivas
, T.B. Powles
, et al.
·
Annals of Oncology
·
14
PDF
LBA110 A blinded, exploratory phase II trial of nivolumab and the GDF-15 neutralizing antibody visugromab or placebo as neoadjuvant treatment of patients with muscle-invasive bladder cancer (MIBC): Primary results of the GDFather-NEO trial
2025
·
A. Necchi
, C. Mercinelli
, et al.
·
Annals of Oncology
·
6
PDF
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study
2025
·
B.A. Maiorano
, A. Cigliola
, et al.
·
ESMO Open
·
4
PDF
SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer
2024
·
J.W.F. Catto
, A. Necchi
, et al.
·
European Urology
·
3
FIERCE-21: Phase 2 study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUCC)
2019
·
A. Necchi
, D. Castellano
, et al.
·
European Urology Supplements
·
3
Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma
2018
·
A. Necchi
, L. Mariani
, et al.
·
European Urology Supplements
·
3
Final prespecified analysis of the phase III LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti–PD-(L)1 therapy
2026
·
D.Y.C. Heng
, M. Schmidinger
, et al.
·
Annals of Oncology
·
2
PDF
Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials
2026
·
A. Cigliola
, A. Larcher
, et al.
·
ESMO Open
·
2
PDF
3069MO Health-related quality of life (HRQoL) outcomes from the NIAGARA trial of perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC)
2025
·
M.S. van der Heijden
, T.B. Powles
, et al.
·
Annals of Oncology
·
2
Neoadjuvant nivolumab plus gemcitabine–cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine–cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial
2026
·
G. Sonpavde
, M.S. van der Heijden
, et al.
·
Annals of Oncology
·
1
PDF
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study
2026
·
A. Cigliola
, B.A. Maiorano
, et al.
·
ESMO Open
·
1
PDF
3135eTiP INTerpath-011: Phase II study of intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-Guérin (BCG) versus BCG alone for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC)
2025
·
P. Grivas
, A.M. Kamat
, et al.
·
Annals of Oncology
·
1
100P Co-mutational landscape of key fibroblast growth factor receptor (FGFR) alterations in intra-hepatic cholangiocarcinoma (iCCA), bladder cancer (BC) and glioma
2022
·
A. Necchi
, K. Murugesan
, et al.
·
Annals of Oncology
·
1
Contemporary outcomes of salvage high-dose chemotherapy in advanced germ cell tumors: an analysis of the cellular therapy and immunobiology working party of the EBMT registry
2026
·
V. Tateo
, M. Longoni
, et al.
·
ESMO Open
PDF
Integrating China’s Oncology Innovations into the Global Landscape: A Strategic Blueprint for Precision, Partnership, and Purpose
2026
·
Xudong Ni
, Tingwei Zhang
, et al.
·
Cancer Discovery
2610MO Genomic analysis of papillary renal cell carcinoma (PRCC): MET alterations are uncommon and enriched in patients of African ancestry
2025
·
M. Zugman
, D.C. Pavlick
, et al.
·
Annals of Oncology
WITHDRAWN: 2683eTiP TEM-GU: A phase I/II clinical study of a genetically-modified Tie-2 expressing monocytes in patients with metastatic renal cell carcinoma
2025
·
A. Necchi
, A. CAPOTONDO
, et al.
·
Annals of Oncology
3117eP ERBB3-altered clinically advanced urothelial bladder cancer: Genomic landscape study and therapeutic possibilities
2025
·
S. Blinka
, D.C. Pavlick
, et al.
·
Annals of Oncology
PDF
1047P Contemporary outcomes of salvage high-dose chemotherapy (HDCT) in advanced germ cell tumors (GCTs): An analysis of the European Society for blood and marrow transplantation (EBMT) registry
2025
·
V. Tateo
, M. Longoni
, et al.
·
Annals of Oncology
P254 REAl-world Data from an Italian Compassionate Use Program (CUP) of avelumab first- Line Maintenance (1LM) for locallY advanced or metastatic Urothelial Carcinoma (la/mUC): Outcomes from the READY study in patients (pts) with low tumor burden
2024
·
L. Antonuzzo
, M. Maruzzo
, et al.
·
European Urology Open Science
2024TiP NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring
2024
·
V. Tateo
, A. Cigliola
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
38
Citation count:
181
H-index:
6
I10-index:
5
Year
Topic
Type